Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 19, 3674-3681
Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of autosomal dominant Parkinson’s disease (PD) and have been associated with familial and sporadic PD. Reducing the kinase activity of LRRK2 is a promising therapeutic strategy since pathogenic mutations increase the kinase activity. Several small-molecule LRRK2 inhibitors are currently under investigation for the treatment of PD. However, drug discovery and development are always accompanied by high costs and a risk of late failure. The use of already approved drugs for a new indication, which is known as drug repositioning, can reduce the cost and risk.Keywords
Funding Information
- Bundesministerium für Wirtschaft und Energie
- Bundesministerium für Forschung, Technologie und Raumfahrt (03EFISN108)
This publication has 63 references indexed in Scilit:
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Extended-Connectivity FingerprintsJournal of Chemical Information and Modeling, 2010
- Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's diseaseBiochemical Journal, 2009
- Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPaseProceedings of the National Academy of Sciences, 2008
- A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activitiesAnnals of Oncology, 2007
- Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunctionExpert Opinion on Pharmacotherapy, 2007
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004
- High-affinity binding of [3H]paroxetine to caudate nucleus and microvessels from porcine brainNeuroReport, 1996